Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Extracorporeal Shock Wave Therapy With or Without Kinesiotaping for Plantar Fasciitis

NCT07864948 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-08-27
Last updated
2026-10-08

Condition(s) studied

Plantar Fasciitis

Investigational drug(s) / intervention(s)

Kinesio TapingExtracorporeal Shock Wave Therapy (ESWT)

Kinesio Taping: Kinesiology tape applied twice (once a week for 2 weeks) with mechanical correction and tension

Extracorporeal Shock Wave Therapy (ESWT): Patients will receive 3 sessions of focused ESWT at 1-week intervals (1800 to 2000 impulses per session at 0.20-0.30 mJ/mm²

Study summary

This study aims to evaluate and compare the short- and mid-term effects of Extracorporeal Shock Wave Therapy (ESWT) alone versus a combination of ESWT and Kinesio Taping (KT) on pain, foot functionality, and plantar fascia thickness in patients with plantar fasciitis.

A total of 48 patients with chronic plantar fasciitis will be included in this prospective, randomized controlled trial and randomly allocated into two groups: the ESWT group and the ESWT + Kinesio Taping group.

Primary outcome measures include pain severity assessed via the Visual Analog Scale (VAS) for morning and general pain, foot functionality evaluated using the Foot Function Index (FFI), and plantar fascia thickness measured via ultrasonography. Evaluations will be conducted at baseline, immediately post-treatment, and at the 3-month follow-up.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: Age between 18 and 65 years Chronic heel pain for at least 3 months Localized pain and tenderness on palpation at the medial aspect of the calcaneal tuberosity with the ankle in full dorsiflexion Pain intensity of 50 mm or greater on the Visual Analog Scale (VAS) during the first step in the morning Ultrasonographic findings typical of plantar fasciitis (proximal plantar fascia thickness greater than 4 mm with alterations in the fibrillar pattern) Willingness to participate in the study and provide written informed consent Exclusion Criteria: Presence of any skin lesions or integrity disruption in the heel region History of inflammatory or rheumatic arthritis History of fracture, trauma, or surgery in the heel region Presence of systemic infection or malignancy Presence of a cardiac pacemaker Local injection into the heel region within the last 6 months, or use of topical or oral non-steroidal anti-inflammatory drugs (NSAIDs) within the last 2 weeks Unwillingness to participate in the study

Primary outcome measure(s)

  • Change in Visual Analog Scale (VAS) Score for Pain — Baseline, immediately post-treatment, and at 3-month follow-up
  • Change in Foot Function Index (FFI) Score — Baseline, immediately post-treatment, and at 3-month follow-up
  • Change in Plantar Fascia Thickness Measured by Ultrasonography — Baseline, immediately post-treatment, and at 3-month follow-up

Trial sites (1)

FacilityCityRegionStatus
Ankara Bilkent City Hospital Ankara Çankaya Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07864948 on ClinicalTrials.gov ↗ ← All trials in Turkey